-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ravulizumab LA in Lupus Nephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ravulizumab LA in Lupus Nephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ravulizumab LA in Lupus Nephritis Drug Details: Ravulizumab (Ultomiris) is a...
-
Product Insights
Leishmaniasis (Kala-Azar) – Drugs In Development, 2023
Global Markets Direct’s, ‘Leishmaniasis (Kala-Azar) - Drugs In Development, 2023’, provides an overview of the Leishmaniasis (Kala-Azar) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Lung Adenocarcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Lung Adenocarcinoma - Drugs In Development, 2023’, provides an overview of the Lung Adenocarcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lung Adenocarcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Trypanosomiasis – Drugs In Development, 2023
Global Markets Direct’s, ‘Trypanosomiasis - Drugs In Development, 2023’, provides an overview of the Trypanosomiasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Trypanosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PHI-101 in Refractory Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PHI-101 in Refractory Acute Myeloid Leukemia Drug Details:PHI-101 is under development for the treatment of relapsed...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BNT-142 in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BNT-142 in Metastatic Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BNT-142 in Metastatic Ovarian Cancer Drug Details: BNT-142 is under development...
-
Sector Analysis
Contract Pharmaceutical Dose Manufacturing Industry – Composition, Size, Market Share and Outlook, 2023 Edition
Contract Pharmaceutical Dose Manufacturing Industry Overview The total dose CMO contract revenue in 2022 represented significant growth over 2021 revenue. The growth rate was the highest recorded since 2011 for commercial contract dose manufacturing revenues, and surprisingly adds to the strong growth experienced in 2021, despite demand for COVID-19 vaccines and therapies waning in 2022. The Contract Pharmaceutical Dose Manufacturing Industry report is a comprehensive look at the finished dose contract manufacturing landscape in 2023. It includes an analysis of...
-
Product Insights
El-Fayum Development Lease Field, Egypt
El-Fayum Development Lease Field is a producing field located in Faiyum Governorate, Egypt. It is being operated by IPR Lake Qarun Petroleum Co. Empower your strategies with our El-Fayum Development Lease Field, Egypt report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered...
-
Company Profile
Ra Medical Systems Inc – Company Profile
Catheter Precision Inc (Catheter Precision), formerly Ra Medical Systems Inc, is a medical device company that develops, commercializes, and markets its advanced excimer laser-based technology to treat vascular and dermatological immune-mediated inflammatory illnesses. The company’s product portfolio includes VIVO System, LockeT and Amigo Remote Catheter System. View into Ventricular Onset technology or VIVO System, is a non-invasive imaging technology that provides 3D cardiac mapping to assist in locating the locations of origin of idiopathic ventricular arrhythmias in patients with structurally...
Add to Basket